Affiliated Hospital of Hebei University, Baoding, Hebei Province, China.
Medicine (Baltimore). 2021 Jan 29;100(4):e23675. doi: 10.1097/MD.0000000000023675.
At present, laser is regarded as an effective treatment for macular edema secondary to branch retinal vein occlusion. With the breakthrough of anti-vascular endothelial growth factor drugs in ophthalmology clinical research, the intravitreal injection of ranibizumab is widely applied, but both methods have their limitations, so some clinical studies have combined and applied them together. However, the clinical results are inconsistent and controversial, and there is no relevant system evaluation for the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion now.
Meta analysis is used to analyze and evaluate the effectiveness and safety of the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion.
CNKI, VIP, WANFANG, China Biology Medicine disc, Web of Science, PubMed, Embase, Cochrane Library have used random controlled clinical trial of laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion from the establishment of the database to October 2020. Two researchers conducted independent screening, quality assessment and data extraction for the literatures, and used RevMan5.3 to conduct Meta analysis for the included literatures.
The research has evaluated the effectiveness and safety of the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion through the aspects of the best corrected visual acuity 6 months after operation, macular center thickness and the incidence of adverse reactions such as elevated intraocular pressure, endophthalmitis, vitreous hemorrhage and cataract.
Laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion has good effect, and the research has provided reliable evidence for the use of clinical treatment of the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion.
目前激光被认为是治疗分支静脉阻塞性视网膜静脉阻塞继发黄斑水肿的有效方法。随着抗血管内皮生长因子药物在眼科临床研究中的突破，玻璃体内注射雷珠单抗得到了广泛应用，但两种方法都有其局限性，因此一些临床研究将两者结合应用。但临床结果并不一致，存在争议，目前尚无关于激光联合玻璃体内注射雷珠单抗治疗分支静脉阻塞性视网膜静脉阻塞继发黄斑水肿的系统评价。
采用 Meta 分析方法对激光联合玻璃体内注射雷珠单抗治疗分支静脉阻塞性视网膜静脉阻塞继发黄斑水肿的有效性和安全性进行分析评价。
计算机检索中国知网、维普、万方、中国生物医学文献数据库、Web of Science、PubMed、Embase、 Cochrane Library 数据库，从建库至 2020 年 10 月，关于激光联合玻璃体内注射雷珠单抗治疗分支静脉阻塞性视网膜静脉阻塞继发黄斑水肿的随机对照临床试验。由 2 位研究者独立进行文献筛选、质量评价和数据提取，并采用 RevMan5.3 软件进行 Meta 分析。
从术后 6 个月最佳矫正视力、黄斑中心厚度和眼压升高、眼内炎、玻璃体积血、白内障等不良反应发生率方面评价了激光联合玻璃体内注射雷珠单抗治疗分支静脉阻塞性视网膜静脉阻塞继发黄斑水肿的有效性和安全性。
激光联合玻璃体内注射雷珠单抗治疗分支静脉阻塞性视网膜静脉阻塞继发黄斑水肿效果较好，为临床应用激光联合玻璃体内注射雷珠单抗治疗分支静脉阻塞性视网膜静脉阻塞继发黄斑水肿提供了可靠证据。
